TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of
35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic Retinopathy Market has also been witnessing the Increased Focus on Combination Therapies. However, the Availability of Effective Surgical Treatments could pose a challenge to the growth of this market.
Buy a copy of this report: http://www.researchmoz.us/sample/checkout.php?rep_id=167854&type=S
TechNavio's report, the Global Diabetic Retinopathy Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC region; it also covers the Global Diabetic Retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Eli Lilly and Co., Novartis International AG, Pfizer Inc., and Roche Holding Ltd.
Other vendors mentioned in the report are Alcon Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Anadys Pharmaceuticals Inc., Antisense Therapeutics Ltd., Boehringer Ingelheim GmbH, DeveloGen AG, Excaliard Pharmaceuticals Inc., Eyetech Inc., Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., iCo Therapeutics Inc., Intercell AG, Isis Pharmaceuticals Inc., King Pharmaceuticals Inc., Lpath Inc., Lupin Ltd., mtm laboratories AG, Novagali Pharma SA, Novast Laboratories Ltd., OPKO Health Inc., PAREXEL International Corp., pSivida Corp., Quark Pharmaceuticals Inc., Sirnaomics Inc., ThromboGenics NV, Torrent Pharmaceuticals Ltd., and Vitreoretinal Technologies Inc.
Buy a copy of this report: http://www.researchmoz.us/sample/checkout.php?rep_id=167854&type=S
TechNavio's report, the Global Diabetic Retinopathy Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC region; it also covers the Global Diabetic Retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Eli Lilly and Co., Novartis International AG, Pfizer Inc., and Roche Holding Ltd.
Other vendors mentioned in the report are Alcon Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Anadys Pharmaceuticals Inc., Antisense Therapeutics Ltd., Boehringer Ingelheim GmbH, DeveloGen AG, Excaliard Pharmaceuticals Inc., Eyetech Inc., Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., iCo Therapeutics Inc., Intercell AG, Isis Pharmaceuticals Inc., King Pharmaceuticals Inc., Lpath Inc., Lupin Ltd., mtm laboratories AG, Novagali Pharma SA, Novast Laboratories Ltd., OPKO Health Inc., PAREXEL International Corp., pSivida Corp., Quark Pharmaceuticals Inc., Sirnaomics Inc., ThromboGenics NV, Torrent Pharmaceuticals Ltd., and Vitreoretinal Technologies Inc.
Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
COMPLETE REPORT WITH TOC: http://www.researchmoz.us/global-diabetic-retinopathy-market-2012-2016-report.html
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.